- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Bryan Smith, PhD
Instructor, Radiology and Molecular Imaging Program
American Association for Cancer Research
- Seeking to design rationally-engineered nanotherapies for treatment of triple negative breast cancer.
- A nanoparticle drug delivery system that targets specific tumor-promoting immune cells is tested in laboratory models of triple negative breast cancer.
- If successful, this study will enable rapid translation of a nanoparticle platform to benefit patients.
In order to grow and spread, tumors require help from neighboring cells and effectively recruit circulating cells, like immune cells, to the tumor bed. These cells help to provide the right environment to support tumor growth and invasion into local tissue. Certain types of immune cells called MDSCs also help to mask the tumors from the immune system by shutting down the normal anti-tumor immune response. Dr. Smith is working to develop a targeted therapy that will kill MDSCs and restore the anti-tumor immune response.
Full Research Summary
Our immune system continually surveils our bodies and eliminates most cancer cells before they become established tumors. Growing tumors, however, can suppress the immune system by recruiting immune cells called myeloid-derived suppressor cells (MDSCs). These specialized cells act to suppress the immune system, allowing the tumors to grow unimpeded and resist anti-cancer therapy. Targeting MDSCs is a compelling strategy to improve response to therapy and treatment outcomes.
Laboratory studies have shown that blocking MDSCs has a dramatic effect on response to anti-cancer drugs. Some of these strategies are being tested in clinical trials but are limited in their clinical efficacy due to side effects.
As part of his American Association of Cancer Research/BCRF award, Dr. Smith has developed a drug-loaded nanoparticle that releases a drug payload to kill MDSCs, while sparing healthy cells and preserving anti-cancer immunity. His laboratory experiments have shown that the system effectively targets the MDSCs. In the second part of his study, he will test the drug-loaded particles in laboratory models of triple negative breast cancer.
This precise targeting of MDSCs could improve the clinical utility of this therapy and make it a viable strategy to improve the effectiveness of anti-cancer therapies.
Dr. Bryan R. Smith is an Instructor in the Department of Radiology and the Molecular Imaging Program at Stanford (MIPS) at Stanford University. He received BS degrees in Physics, Mathematics, and Biomedical Engineering. He was awarded a PhD at The Ohio State University in Biomedical Engineering as an NSF Pre-Doctoral Fellow. At Stanford, Dr. Smith has received many awards and published dozens of nanomedicine and oncology articles in journals ranging from Nature Nanotechnology and Nano Letters to Cancer Research and PNAS and has several patents issued and pending. His lab focuses on the development of nano-enabled immuno-imaging and immunotherapy platforms.